English

Introduction

Dear participant,
You are invited to take part in this research to understand the treatment preferences of patients with Hidradenitis Suppurativa. This study is being conducted in several countries and supervised by the Department of Health Services Research of Maastricht University, The Netherlands.

Hidradenitis Suppurativa (HS) is an inflammatory skin disease with a profound effect on patients' quality of life. The patient's journey to manage HS is often complex and unsuccessful, which motivates the aim of this research to gain insight into the preferences and relevant treatment considerations from the perspective of patients. To date, preference research has been conducted extensively in skin conditions like psoriasis and atopic dermatitis, but not yet in HS. Your contribution will enable us to conduct this first-of-a-kind research in HS to improve future treatment outcomes in HS.

Your participation is entirely voluntary, and your data will be protected according to relevant regulations. Your responses will be treated as strictly confidential, anonymized and only used for the purposes of this study, you may withdraw from this research at any time. Please be reminded that there are no right or wrong answers to this questionnaire as we are mainly interested in your personal preferences in treatment decision-making, which are informed by your personal opinion and experiences.

This questionnaire will take approximately 30 minutes to complete. Please take your time to read and follow the instructions carefully. All questions must be completed because incomplete questionnaires will make the analysis impossible. Some questions may appear repetitive, but your conscious decision-making for every question is expected from you.

Thank you very much for your participation.

Should you have any questions or problems completing this survey, please reach out to dmw.willems@maastrichtuniversity.nl

Informed consent for participation:

1. I confirm that I have read and understood the information sheet (previous section) for the above study;

2. I understand that my participation is voluntary, and I am free to withdraw at any time, without giving any reasons, without my medical care or legal rights being inflicted;

3. I understand any data will be protected and anonymized by strict adherence to applicable data safeguarding requirements;

4. I agree to take part in the above study.

Please indicate that you agree to above terms by selecting "Yes"

Yes
No

Participant information

What is your country of residence?

What is your age?

What is your gender?

What is your Race or Ethnicity?

What is your current occupational status?

What is your highest level of education?

How many years ago were you diagnosed with Hidradenitis Suppurativa?

Which of the following best describes your Hidradenitis Suppurativa at the moment?

Have you taken a biological therapy (e.g. Humira) to treat your Hidradenitis Suppurativa in the past?

Yes

No

Have you had excisional surgery to treat your Hidradenitis Suppurativa in the past?

Yes

No

What is your current level of pain?

0= no pain at all

10 = worst level of pain

0 1 2 3 4 5 6 7 8 9 10

0= no pain at all

10 = worst level of pain

	0	1	2	3	4	5	6	7	8	9	10
Your level of pain today											

Assessment of your Quality of Life using HiSQoL

In the past 7 days, how much has your Hidradenitis Suppurativa caused problems with walking (not for exercise):

Unable to do due to my HS | Extremely | Very much | Moderately | Slightly | Not at all

In the past 7 days, how much has your Hidradenitis Suppurativa caused problems with exercising (for example: swimming, jogging, yoga etc.):

Unable to do due to my HS | Extremely | Very much | Moderately | Slightly | Not at all

In the past 7 days, how much has your Hidradenitis Suppurativa caused problems with sleeping:

Extremely | Very much | Moderately | Slightly | Not at all

In the past 7 days, how much has your Hidradenitis Suppurativa caused problems with washing yourself:

Extremely | Very much | Moderately | Slightly | Not at all

In the past 7 days, how much has your Hidradenitis Suppurativa caused problems with getting dressed:

Extremely | Very much | Moderately | Slightly | Not at all

In the past 7 days, how much has your Hidradenitis Suppurativa caused problems with your concentration:

Extremely | Very much | Moderately | Slightly | Not at all

In the past 7 days, how have your current or potential new skin lesions influenced what you wear to avoid discomfort:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how bothered have you been by pain:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how bothered have you been by itch:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how bothered have you been by drainage:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how bothered have you been by odor:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how much has Hidradenitis Suppurativa caused you to feel down or depressed:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how much has Hidradenitis Suppurativa caused you to feel embarrassed:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how much has Hidradenitis Suppurativa caused you to feel anxious or nervous:

Extremely Very much Moderately Slightly Not at all

In the past 7 days, how much has Hidradenitis Suppurativa made sexual activity difficult:

I am not sexually active | I am unable to due to my HS | Extremely | Very much | Moderately | Slightly | Not at all

In the past 7 days, how much has Hidradenitis Suppurativa affected your desire for sexual activities:

Extremely	Very much	Moderately	Slightly	Not at all

In the past 7 days, how much has Hidradenitis Suppurativa influenced your ability to work or study

I do not work or study	Unable to do due to my HS	Extremely	Very much	Moderately	Slightly	Not at all

Assessment of your Quality of Life using EQ-5D

Mobility

	I have no problems walking about	I have slight problems walking about	I have moderate problems walking about	I have severe problems walking about	I am unable to walk
Mobility	○	○	○	○	○

Self-Care

	I have no problems washing or dressing myself	I have slight problems washing or dressing myself	I have moderate problems washing or dressing myself	I have severe problems washing or dressing myself	I am unable to washing or dress myself
Self-Care	○	○	○	○	○

Usual Activities

	I have no problems doing my usual activities	I have slight problems doing my usual activities	I have moderate problems doing my usual activities	I have severe problems doing my usual activities	I am unable to do my usual activities
Usual Activities	○	○	○	○	○

Pain / Discomfort

	I have no pain or discomfort	I have slight pain or discomfort	I have moderate pain or discomfort	I have severe pain or discomfort	I have extreme pain or discomfort
Pain / Discomfort	○	○	○	○	○

Anxiety / Depression

	I am not anxious or depressed	I am slightly anxious or depressed	I am moderately anxious or depressed	I am severely anxious or depressed	I am extremely anxious or depressed
Anxiety / Depression	○	○	○	○	○

Introduction to preference questions

Explanation of the next task

In the next task, we are interested to understand your preferences in the management of HS. We would like to ask you to make a series of choices between two hypothetical treatment options and their associated outcomes. To do this, please read the following information carefully:

You will be presented with 2 hypothetical treatment options (Treatment A and Treatment B) for the management of HS. Treatment A and Treatment B are hypothetical and are intended to provide you with different treatment outcomes. In each of the following 15 questions, you will be asked to state whether you would prefer Treatment A or Treatment B to treat your HS. There is no wrong or right answer, we are only interested in your personal preference for one treatment option over the other.

Explanation of the Questions

Treatment A and Treatment B will vary on the following characteristics for you:

Effectiveness: Percentage reduction of the number of painful, inflammatory lesions on your skin

a. 25% reduction of the number of inflammatory lesions or nodules on your skin, or
b. 50% reduction of the number of inflammatory lesions or nodules on your skin, or
c. 75% reduction of the number of inflammatory lesions or nodules on your skin, or
d. 100% reduction of the number of inflammatory lesions or nodules on your skin

***Explanation**:* In clinical studies of HS, effectiveness is assessed as the percentage reduction of number of skin abscesses, nodules or lesions due to treatment. The treatment options presented to you offer either a 25%, 50%, 75% or 100% reduction of the number of painful, inflammatory lesions on your skin. In your decision-making, please consider the impact a reduction of the number of painful, inflammatory lesions on your skin may have on your quality of life and wound dressing needs.

Pain: Reduction of pain

a. Small pain relief, corresponding to a 1-point reduction in pain on a scale of 0–10, or
b. Moderate pain relief, corresponding to a 3-point reduction in pain on a scale of 0–10, or
c. Almost complete pain relief, corresponding to a 6-point reduction in pain on a scale of 0–10

***Explanation*:** Pain is known to cause a severe impact on the quality of life of patients living with HS. The treatment options presented to you offer either a 1-,3- or 6-point reduction of pain on a scale of 0-to-10. Almost complete pain relief corresponds to absence of HS-specific pain.

Duration of treatment benefit: The duration during which the treatment is able to provide the outlined effectiveness and pain relief.

a. 6 months, or
b. 12 months, or
c. 24 months

***Explanation*:** The treatment options presented to you offer either 6-, 12-, or 24- months duration during which the outlined effectiveness and pain relief are maintained (while you are adhering to the therapy). After this period, the treatment effects are expected to decrease and cannot be re-gained with the same treatment.

Risk of mild side effect: Annual risk of experiencing mild side effects while taking the medicine.

a. 100 people out of 1000 (10%), or
b. 300 people out of 1000 (30%), or
c. 500 people out of 1000 (50%)

Explanation: The treatment options presented to you are generally considered safe, but have different risks of mild side effects, which for example can be headache or nausea.

Risk of serious infection: Annual risk of experiencing a serious infection while taking the medicine.

a. 1 person out of 1000 (0.1%), or
b. 10 people out of 1000 (1%), or
c. 30 people out of 1000 (3%)

Explanation: The treatment options presented to you are generally considered safe but have different risks of causing serious infections that may lead to hospitalization, which for example can be a common cold, bronchitis or bladder infection.

Mode of administration: How the treatment is provided to you:

a. Oral tablet, to be taken every day, or
b. Subcutaneous injection, once every 2 weeks at home or in a clinic, or
c. Intravenous injection, once every 4 weeks in a clinic or hospital setting

Explanation: The treatment options presented to you can be given as:

- Oral tablet: 1 tablet per day, neutral in taste, to be taken daily at a specific time, or

- Subcutaneous injection: 1 injection under the skin every 2 weeks by a doctor or nurse at home or at doctor's clinic, or
- Intravenous injection: 1 injection into the vein every 4 weeks by an infusion 'drip' in a clinic or hospital setting. The infusion usually takes approximately 15 minutes.

Example Question (do not fill in):

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 75% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on scale of 0-10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 subcutaneous injection every 2 weeks

Treatment A | Treatment B

The example illustrates that the participant preferred Treatment A over Treatment B.

Next, you will be asked to indicate your treatment preference repeatedly for 15 scenarios, please answer each question carefully .

Patient Preference questions (Block 1)

Now it is your turn to choose:

Which treatment option would you prefer? (1/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 75% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on scale of 0-10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (2/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 50% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (3/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 100% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on scale of 0-10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (4/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 100% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (5/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 50% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (6/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 75% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on scale of 0-10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (7/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 50% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (8/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 100% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (9/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 75% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (10/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 25% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on scale of 0-10	**Moderate complete pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (11/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 25% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on scale of 0-10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (12/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 25% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on scale of 0-10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (13/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 75% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on scale of 0-10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (14/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 75% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on scale of 0-10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (15/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 75% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on scale of 0-10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Patient Preference questions (Block 2)

Now it is your turn to choose:

Which treatment option would you prefer? (1/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 100% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on scale of 0-10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (2/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 50% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on scale of 0-10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (3/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 75% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (4/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 100% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (5/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 50% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (6/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 75% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (7/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 25% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (8/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 100% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (9/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 25% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (10/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 75% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (11/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 100% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (12/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 50% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (13/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 100% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (14/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 25% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (15/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 75% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Patient Preference questions (Block 3)

Now it is your turn to choose:

Which treatment option would you prefer? (1/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 100% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (2/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 50% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (3/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 25% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (4/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 75% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (5/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 100% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (6/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 25% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 subcutaneous injection every 2 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (7/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 50% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (8/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 100% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on scale of 0-10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (9/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 100% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (10/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 100% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 500 people out of 1000 (50%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (11/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 25% Reduction	 50% Reduction
Pain Reduction of pain	**Moderate pain relief** 3-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	24 Months	6 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (12/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 50% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 300 people out of 1000 (30%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 10 people out of 1000 (1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Which treatment option would you prefer? (13/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 75% Reduction	 50% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Small pain relief** 1-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 100 people out of 1000 (10%)
Risk of serious infection Annual risk to experience a serious infection	 10 people out of 1000 (1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 intravenous injection every 4 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (14/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 100% Reduction	 25% Reduction
Pain Reduction of pain	**Almost complete pain relief** 6-point reduction on a scale of 0–10	**Moderate pain relief** 3-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	12 Months	24 Months
Risk of mild side effect Annual risk to experience a mild side effect	 100 people out of 1000 (10%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 1 person out of 1000 (0.1%)	 30 people out of 1000 (3%)
Mode of administration How the treatment is provided to you	 1 subcutaneous injection every 2 weeks	 1 pill every day

Treatment A

Treatment B

Which treatment option would you prefer? (15/15)

	Treatment A	Treatment B
Effectiveness Percentage reduction of the number of painful, inflammatory lesions on your skin.	 50% Reduction	 25% Reduction
Pain Reduction of pain	**Small pain relief** 1-point reduction on a scale of 0–10	**Almost complete pain relief** 6-point reduction on a scale of 0–10
Duration of treatment benefit The duration during which the treatment provides the outlined benefits	6 Months	12 Months
Risk of mild side effect Annual risk to experience a mild side effect	 300 people out of 1000 (30%)	 500 people out of 1000 (50%)
Risk of serious infection Annual risk to experience a serious infection	 30 people out of 1000 (3%)	 1 person out of 1000 (0.1%)
Mode of administration How the treatment is provided to you	 1 pill every day	 1 intravenous injection every 4 weeks

Treatment A

Treatment B

Completion question

How difficult was the completion of this survey for you?

0 = Not difficult at all

10 = Extremely difficult

0 1 2 3 4 5 6 7 8 9 10

Level of difficulty